- Home
- MDXH vs CUE Comparison
MDXH vs CUE Comparison
Compare MDXH & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- CUE
- Stock Information
- Founded
- MDXH 2003
- CUE 2014
- Country
- MDXH Belgium
- CUE United States
- Employees
- MDXH N/A
- CUE N/A
- Industry
- MDXH
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- MDXH
- CUE Health Care
- Exchange
- MDXH Nasdaq
- CUE Nasdaq
- Market Cap
- MDXH 93.1M
- CUE 94.4M
- IPO Year
- MDXH 2021
- CUE 2018
- Fundamental
- Price
- MDXH $1.86
- CUE $1.32
- Analyst Decision
- MDXH Strong Buy
- CUE Strong Buy
- Analyst Count
- MDXH 2
- CUE 5
- Target Price
- MDXH $7.00
- CUE $5.00
- AVG Volume (30 Days)
- MDXH 58.0K
- CUE 195.8K
- Earning Date
- MDXH 02-26-2025
- CUE 03-10-2025
- Dividend Yield
- MDXH N/A
- CUE N/A
- EPS Growth
- MDXH N/A
- CUE N/A
- EPS
- MDXH N/A
- CUE N/A
- Revenue
- MDXH $84,708,000.00
- CUE $9,532,000.00
- Revenue This Year
- MDXH $28.76
- CUE $73.11
- Revenue Next Year
- MDXH $19.91
- CUE $11.02
- P/E Ratio
- MDXH N/A
- CUE N/A
- Revenue Growth
- MDXH 33.01
- CUE 149.53
- 52 Week Low
- MDXH $1.55
- CUE $0.45
- 52 Week High
- MDXH $3.85
- CUE $2.37
- Technical
- Relative Strength Index (RSI)
- MDXH 41.65
- CUE 48.32
- Support Level
- MDXH $1.82
- CUE $1.22
- Resistance Level
- MDXH $2.01
- CUE $1.54
- Average True Range (ATR)
- MDXH 0.09
- CUE 0.11
- MACD
- MDXH 0.01
- CUE -0.01
- Stochastic Oscillator
- MDXH 46.43
- CUE 35.29
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.